ReviveMed turns drug discovery into a big data problem and raises $1.5M to solve it

What if there's a drug that already exists that could treat a disease with no known therapies, but we just haven't made the connection? Finding that connection by exhaustively analyzing complex biomechanics within the body -- with the help of machine learning, naturally -- is the goal of ReviveMed, a new biotech startup out of MIT that just raised $1.5 million in seed funding. Around the turn of the century, genomics was the big thing. Then, as the power to investigate complex biological processes improved, proteomics became the next frontier. We may have moved on again, this time to the yet more complex field of metabolomics, which is where ReviveMed comes in.